Latest Conference Articles
The OncLive® Conference page includes a listing of all conferences covered by OncLive®, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.
HER2+ Early Breast Cancer: Tailoring Therapy in the Era of Expanding Options
March 7th 2025, 9:54pm
PER® Miami Breast Cancer Conference
Sara A. Hurvitz, MD, FACP, offers insight on the use of (neo)adjuvant therapies in HER2-positive early breast cancer, and how to best optimize treatment.
PF-07248144 Plus Fulvestrant Is Safe, Active in Pretreated ER+/HER2– Metastatic Breast Cancer
March 7th 2025, 9:32pm
PER® Miami Breast Cancer Conference
PF-07248144 plus fulvestrant was safe and generated responses in pretreated estrogen receptor–positive, HER2-negative metastatic breast cancer.
Updated Data Further Support KEYNOTE-522 Regimen as SOC in High-Risk, Early-Stage TNBC
March 7th 2025, 9:21pm
PER® Miami Breast Cancer Conference
Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab provides meaningful OS benefits in high-risk, early-stage TNBC.
Elacestrant Improves PFS Irrespective of ESR1 VAF Level in ER+/HER2-Negative Breast Cancer
March 7th 2025, 9:10pm
PER® Miami Breast Cancer Conference
PFS was extended with elacestrant vs SOC in pretreated, ER-positive, HER2-negative breast cancer, regardless of the level of ESR1 variant allele fraction.
Dr Jagsi on Factors for RT Omission After Breast-Conserving Surgery in Early Breast Cancer
March 7th 2025, 8:40pm
PER® Miami Breast Cancer Conference
Reshma Jagsi, MD, Dphil, discusses factors that could influence the omission of radiation therapy following breast-conserving surgery in early-stage breast cancer.
Dr Borgen on the Need for Improved Risk Stratification in Early-Stage Breast Cancer
March 7th 2025, 8:29pm
PER® Miami Breast Cancer Conference
Patrick I. Borgen, MD, discusses the need for improved risk stratification in early-stage breast cancer.
Imulnestrant Plus Abemaciclib Extends PFS Over SOC in ER+/HER2– Advanced Breast Cancer
March 7th 2025, 7:37pm
PER® Miami Breast Cancer Conference
Imlunestrant generated PFS benefit with or without abemaciclib for select patients with ER-positive, HER2-negative advanced breast cancer.
Sacituzumab Govitecan Upholds Efficacy and Safety in Real-World mTNBC Population
March 7th 2025, 7:05pm
PER® Miami Breast Cancer Conference
Treatment with sacituzumab govitecan was effective and tolerable in real-world patients with mTNBC who received the agent in later-line settings.
Real-World Findings Support the Safety of Frontline Ribociclib Plus ET for HR+/HER2-Negative Metastatic Breast Cancer
March 7th 2025, 6:24pm
PER® Miami Breast Cancer Conference
The real-world use of ribociclib plus ET is in line with recommended dosing and the regimen’s use has been increasing in mBC, according to EHR and KRD data.
Ribociclib Efficacy Is Maintained With Dose Reductions in HR+/HER2-Negative Early Breast Cancer
March 7th 2025, 6:01pm
PER® Miami Breast Cancer Conference
A post hoc analysis of the NATALEE trial suggests that ribociclib dose reduction preserves iDFS in hormone receptor+/HER2-negative early breast cancer.
Sacituzumab Govitecan Produces Comparable Real-World OS Results, Low Rates of Neutropenia in Metastatic TNBC
March 7th 2025, 2:00pm
PER® Miami Breast Cancer Conference
Sacituzumab govitecan was active with low rates of neutropenia—especially in patients receiving G-CSF—in real-world metastatic TNBC.
Dr Coombs on the Challenges in Establishing a Treatment Consensus for Relapsed CLL
March 3rd 2025, 8:24pm
Bridging the Gaps in Leukemia, Lymphoma, and Multiple Myeloma
Catherine C. Coombs, MD, discusses the challenges in establishing a treatment consensus for relapsed CLL.
Efficacy and Safety of Nadofaragene Firadenovec Hold Up in NMIBC Real-World Study
February 27th 2025, 10:00pm
The intravesical therapy nadofaragene firadenovec yielded a 79% 3-month CR rate in patients with CIS with or without papillary disease in a real-world study.
Durvalumab Plus Chemo May be Promising Neoadjuvant Option in UTUC
February 25th 2025, 2:00pm
Genitourinary Cancers Symposium (ASCO GU)
A phase 3 study will be initiated after completion of the first neoadjuvant phase 2 trial of platinum-based chemotherapy plus immunotherapy in UTUC.
Dr Patel on the Potential for Adjuvant Immunotherapy in CSCC
February 24th 2025, 6:59pm
Sapna Patel, MD, discusses the potential for adjuvant immunotherapy in patients with high-risk cutaneous squamous cell carcinoma.
Observation Is a Reasonable Alternative to Adjuvant PD-1 Blockade in Stage IIB/IIIC Melanoma
February 18th 2025, 2:00pm
Tara C. Mitchell, MD, discusses considerations and lingering questions regarding pre- and post-operative management strategies in stage IIB/IIIC melanoma.
Dr Oluwole on CRS and Neurotoxicity Beyond 2 Weeks After Axi-Cel Infusion in R/R LBCL
February 17th 2025, 8:39pm
Transplantation and Cellular Therapy Meetings
Olalekan Oluwole, MD, MPH, discusses the incidence and resolution of CRS and neurological events beyond two weeks following axi-cel infusion in relapsed/refractory LBCL.
Dr Garfall on Ide-Cel and Lenalidomide Maintenance in Myeloma After Suboptimal ASCT Response
February 17th 2025, 8:21pm
Transplantation and Cellular Therapy Meetings
Alfred L. Garfall, MD, MS, discusses data for ide-cel and lenalidomide maintenance in multiple myeloma following a suboptimal response to ASCT and lenalidomide.
Piflufolastat F18 Imaging Is Associated With High Clinician Confidence in Prostate Cancer Management
February 17th 2025, 6:04pm
Genitourinary Cancers Symposium (ASCO GU)
Piflufolastat F18 imaging impacted treatment decisions and was associated with clinician confidence in prostate cancer management.
OPTYX Study Offers Preliminary Glance Into Real-World Use of Relugolix in Advanced Prostate Cancer
February 17th 2025, 5:39pm
Genitourinary Cancers Symposium (ASCO GU)
Patients with advanced prostate cancer who initiated treatment with relugolix indicated various treatment preferences and reasons for therapy initiation.